hepash seeding medium (Biopredic)
Structured Review

Hepash Seeding Medium, supplied by Biopredic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seeding+medium/hepash+seeding+medium/pmc11903783-51-0-4
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile"
Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile
Journal: EMBO Molecular Medicine
doi: 10.1038/s44321-025-00195-6
Figure Legend Snippet: Reagents and tools table
Techniques Used: Sequencing, Isolation, Staining, Plasmid Preparation, Software, Irradiation, In Vivo Imaging
Related Articles
Sequencing:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. Isolation:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. Staining:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. Plasmid Preparation:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. Software:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. Irradiation:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. In Vivo Imaging:Article Title: Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile Article Snippet: recovery medium , Biopredic International , #MIL130. .. |
![IMNM autoantibodies induce hMMT <t>myotube</t> atrophy. A Representative 40x confocal images of myotubes formed in hMMTs within each condition immunostained for sarcomeric α-actinin (SAA, magenta) and counterstained with Hoechst 33,342 (cyan). Scale bar = 50 μm. B Dot plot of hMMT nuclear fusion index for individual hMMTs. C Dot plot of mean SAA positive coverage within flattened confocal stack images for individual hMMTs. D Dot plot of myotube width variation as quantified by the coefficient of variance for single myotubes. n = 146 for (+) and (-) healthy IgG, n = 138 for Ceri, n = 524 for anti-HMGCR, and n = 550 for anti-SRP. E Histogram illustrating myotube diameter frequency across treatment conditions. F Dot plot showing average myotube diameter for individual hMMTs. N = 7 patients for anti-HMGCR + and N = 7 for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p < 0.05,** p < 0.01, *** p < 0.001, and **** p < 0.0001](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2220/pmc12882220/pmc12882220__13395_2025_400_Fig3_HTML.jpg)